Working party membership and contributors

From Clinical Guidelines Wiki


Working party membership and contributors to guidelines and public consultation submissions received

Management Committee

Member name Position
Professor John Thompson AO Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney
Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Professor John Kelly Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne
Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW
A/Professor Susan Neuhaus General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA
Dr Annette Pflugfelder PhD Student, Dermatology Research Centre, School of Medicine, The University of Queensland
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital, NSW
Jutta Thwaites Head, Clinical Guidelines Network (until November 2016)
Laura Wuellner Acting Head, Clinical Guidelines Network (from November 2016)

For details of Working Party authorship and subcommittee membership, please see the List of clinical questions.

Membership: Multidisciplinary Working Party

The Management Committee established a multidisciplinary working party to develop these guidelines.

The multidisciplinary Working Party consists of the Management Committee members, the lead authors for guideline sections, consumer representatives as well as the Cancer Council Australia Project team members.

Role Member name Specialty/position State
Management Committee member, Chair of working party Professor John Thompson AO Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney NSW
Lead Author A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD QLD
Lead Author Dr Matteo Carlino Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia

Clinical Senior lecturer University of Sydney

NSW
Lead Author Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre VIC
Management Committee member

Lead Author

Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC VIC
Lead Author A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney NSW
Lead Author Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney NSW
Lead Author A/Professor T Michael Hughes Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital NSW
Lead Author Professor Richard Kefford AM Professor of Cancer Medicine, Macquarie University NSW
Management Committee member

Lead Author

Professor John Kelly Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne VIC
Management Committee member

Lead Author

Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW NSW
Lead Author Professor Graham Mann Chair, University of Sydney Cancer Research Network and Cancer MDI

Co-Director, Centre for Cancer Research, Westmead Institute of Medical Research Chair, Research Committee, Melanoma Institute Australia, University of Sydney

NSW
Lead Author Dr Victoria Mar Dermatologist and Director, Victorian Melanoma Service, Alfred Health, Melbourne VIC
Lead Author Professor Scott Menzies The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney NSW
Lead Author Professor Michael Millward Professor of Clinical Cancer Research, The University of Western Australia; Consultant Medical Oncologist, Sir Charles Gardiner Hospital WA
Lead Author Dr Rachael Morton Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney NSW
Management Committee member A/Professor Susan Neuhaus General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide SA
Management Committee member Dr Annette Pflugfelder Research Higher Degree Student, The School of Medicine, The University of Queensland QLD
Lead Author Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals NSW
Management Committee member Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW NSW
Lead Author A/Professor Michael Sladden Dermatologist, Tas Derm TAS
Lead Author Professor H Peter Soyer Director, School of Medicine, University of Queensland QLD
Lead Author A/Professor Andrew Spillane Associate Professor, Surgical Oncology, The University of Sydney NSW
Management Committee member

Lead Author

Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital NSW
GP representative Dr Margaret Hardy General practitioner Gladesville Medical NSW
GP representative Dr Paul Fishburn General practitioner NSW
Consumer representative Alison Button-Sloan Patient advocate VIC
Consumer representative Clinton Heal Patient advocate, CEO and Founder, Melanoma WA, 2011 WA Young Australian of the Year WA
Management Committee member

CCA Project Team Lead

Jutta Thwaites Head, Clinical Guidelines Network (until November 2016) NSW
Management Committee member

CCA Project Team Lead

Laura Wuellner Acting Head, Clinical Guidelines Network (from November 2016) NSW

Cancer Council Australia Project Team

Role Member name Specialty/position
CCA Project Team member Jutta Thwaites Head, Clinical Guidelines Network
CCA Project Team member Laura Wuellner Project Manager, Clinical Guidelines Network (until November 2016); Acting Head, Clinical Guidelines Network (from November 2016 to January 2018)
CCA Project Team member Katrina Anderson Project Manager, Clinical Guidelines Network (from November 2016 to December 2017)
CCA Project Team member Tamsin Curtis Project Manager, Clinical Guidelines Network (from March 2018)
CCA Systematic Literature Reviewer Team member Jackie Buck Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until April 2016)
CCA Systematic Literature Reviewer Team member Lani Teddy Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until December 2016)
CCA Systematic Literature Reviewer Team member Lyndal Alchin Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until December 2016)
CCA Systematic Literature Reviewer Team member Tamsin Parrish Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from June 2016 to December 2017)
CCA Systematic Literature Reviewer Team member Meghna Kakani Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017 to December 2017)
CCA Systematic Literature Reviewer Team member Cecilia Taing Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017)

Subcommittee membership for each guideline question

For each guideline question, the guideline question lead author under consultation with the Management Committee established a subcommittee with relevant expert members of the working party and co-opted additional external clinical experts as required.

The role of the subcommittee is to review the draft content for the guideline questions of the section before it is presented to the working party.

Identification and management of high-risk individuals

WHO IS AT HIGH RISK OF MELANOMA?
Question lead: Professor Graham Mann
Subcommittee members
Name Position/speciality
Dr Anne Cust Senior Research Fellow, Public Health, The University of Sydney, NSW
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD
Professor David Whiteman Senior Principal Research Fellow and Head, Cancer Control, Queensland Institute of Medical Research Berghofer Medical Research Institute, QLD
Dr Paul Fishburn GP, The Village Medical Practice, NSW
Professor John Kelly Dermatologist, Victorian Melanoma Service, Alfred Hospital, VIC
Dr Rachael Morton Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney
Dr Victoria Mar Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC

Back to top

Diagnosis

WHAT ARE THE CLINICAL FEATURES OF MELANOMA AND HOW DO ATYPICAL MELANOMAS PRESENT?
Question lead: Dr Victoria Mar
Subcommittee members
Name Position/speciality
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
Professor Stephen Lee AM Professor of Dermatology, The University of Sydney, NSW
Dr Bill Murray Head of Anatomical Pathology, Peter MacCallum Cancer Centre, VIC
Professor John Kelly Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne
WHAT IS THE ROLE OF DERMOSCOPY (AND SEQUENTIAL DERMOSCOPY) IN MELANOMA DIAGNOSIS?
Question lead: Professor Scott Menzies
Subcommittee members
Name Position/speciality
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
A/Professor Pascale Guitera Senior Research Fellow, Dermatology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD
WHAT IS THE ROLE OF AUTOMATED INSTRUMENTS IN MELANOMA DIAGNOSIS?
Question leads: Prof Scott Menzies
Subcommittee members
Name Position/speciality
A/Prof Pascale Guitera Senior Research Fellow, Dermatology, The University of Sydney, NSW
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
Prof H Peter Soyer Director, School of Medicine, University of Queensland, QLD
WHAT IS THE ROLE OF CONFOCAL MICROSCOPY IN MELANOMA DIAGNOSIS?
Question leads: A/Prof Pascale Guitera
Subcommittee members
Name Position/speciality
Prof Scott Menzies The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
Prof H Peter Soyer Director, School of Medicine, University of Queensland, QLD
WHAT IS THE ROLE OF SKIN SURFACE IMAGING (TOTAL BODY PHOTOGRAPHY) IN THE EARLY DIAGNOSIS OF PATIENTS AT HIGH RISK OF DEVELOPING MELANOMA?
Question leads: Professor John Kelly and Dr Nikki Adler
Subcommittee members
Name Position/speciality
Dr Paul Fishburn General practitioner
A/Prof Pascale Guitera Senior Research Fellow, Dermatology,The University of Sydney
Clinton Heal Patient advocate
Alison Button-Sloan Patient advocate

Back to top

Biopsy

WHAT TYPE OF BIOPSY SHOULD BE PERFORMED FOR A PIGMENTED SKIN LESION SUSPICIOUS FOR MELANOMA?
Question lead: Professor John Kelly
Subcommittee members
Name Position/speciality
Dr Trevor Beer Histopathologist, Clinipath Pathology, WA
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Jonathan Ng Honorary Research Fellow, Victorian Melanoma Service, The Alfred Hospital, VIC
Dr Joseph Ohana GP, The Village Medical Practice, NSW
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD


WHAT CLINICAL INFORMATION SHOULD THE PATHOLOGIST GIVE THE CLINICIAN TO AID DIAGNOSIS OF MELANOMA?
Question lead: Professor Richard Scolyer
Subcommittee members
Name Position/speciality
A/Professor Brendon Coventry Associate Professor, Department of Surgery, The University of Adelaide; Senior Consultant Surgeon, Royal Adelaide Hospital, SA
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor Stephen Lee AM Professor of Dermatology, The University of Sydney, NSW
Professor Catriona McLean Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital, VIC

Back to top

Management of primary melanoma and lentigo maligna

EXCISION MARGINS FOR MELANOMA
Question lead: A/Professor Michael Sladden
Subcommittee members
Name Position/speciality
Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney, NSW
Professor Omgo Nieweg Surgeon, Melanoma Institute Australia, NSW
WHEN IS SENTINEL NODE BIOPSY INDICATED?
Question lead: Dr David Gyorki
Subcommittee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Victoria Mar Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC
Dr Mark Hanikeri Director, Western Australia Plastic Surgery Centre, WA
Dr Shahneen Sandhu Medical Oncologist, Peter MacCallum Cancer Centre, VIC
SHOULD PATIENTS WITH A POSITIVE SENTINEL LYMPH NODE BIOPSY HAVE A COMPLETE NODE DISSECTION?
Question lead: A/Professor Andrew Spillane
Subcommittee members
Name Position/speciality
Dr Frank Bruscino-Raiola Consultant Plastic Surgeon, Alfred Health, VIC
Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre, VIC
Dr Julie Howle Senior Lecturer, Surgery, The University of Sydney, NSW
Dr Chris McCormack Consultant Dermatologist, St Vincents Hospital Melbourne, VIC
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
PRIMARY DESMOPLASTIC AND NEUROTROPIC MELANOMAS
Question lead: A/Professor T Michael Hughes
Subcommittee members
Name Position/speciality
Professor John Kelly Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
A/Professor Jonathan Stretch AM Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW
Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre, VIC
A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW
Dr Alex Varey Staff Specialist, Department of Plastic and Maxillofacial Surgery, Westmead Hospital, Sydney, Australia
WHAT ARE THE MOST EFFECTIVE TREATMENT/MANAGEMENT INTERVENTIONS TO IMPROVE OUTCOMES IN PATIENTS WITH LENTIGO MALIGNA?
Question lead: Professor H Peter Soyer
Subcommittee members
Name Position/speciality
A/Professor Pascale Guitera Senior Research Fellow, Dermatology, The University of Sydney, NSW
A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
A/Professor Jonathan Stretch AM Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW
Dr Geoff Strutton Anatomical Pathologist, Princess Alexandra Hospital, QLD

Back to top

Investigations and follow-up

WHAT INVESTIGATIONS SHOULD BE PERFORMED FOLLOWING A DIAGNOSIS OF PRIMARY CUTANEOUS MELANOMA FOR ASYMPTOMATIC STAGE I AND II PATIENTS?
Question lead: Dr Rachael Morton
Subcommittee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Victoria Mar Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN IN TRANSIT AND/OR REGIONAL NODE DISEASE (STAGE III MELANOMA) IS DIAGNOSED?
Question lead: Dr Robyn Saw
Subcommittee members
Name Position/speciality
Dr Andrew Haydon Medical Oncologist, Alfred Hospital and Cabrini Health, VIC
Professor Grant McArthur Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC
WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN STAGE IV MELANOMA IS DIAGNOSED?
Question lead:Professor Michael Millward
Subcommittee members
Name Position/speciality
Dr Victoria Atkinson Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD
Dr Michael Brown Medical Oncologist, Royal Adelaide Hospital, SA
Dr Andrew Haydon Medical Oncologist, Alfred Hospital and Cabrini Health, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
HOW SHOULD PATIENTS AT EACH STAGE OF MELANOMA BE FOLLOWED AFTER INITIAL DEFINITIVE TREATMENT?
WHAT ARE THE IDEAL SETTINGS, DURATION AND FREQUENCY OF FOLLOW-UP FOR PATIENTS WITH MELANOMA?
Question lead: A/Professor Andrew Barbour
Subcommittee members
Name Position/speciality
A/Professor Alexander Guminski Associate Professor, Medicine, The University of Sydney, Medical Oncologist, Melanoma Institute Australia, North Shore Private Hospital, and Royal North Shore Hospital, NSW
Wenyuan Liu Dermatologist, Alfred Hospital, Peter MacCallum Cancer Centre, Victorian Melanoma Service, VIC
Professor Scott Menzies The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW
Dr Rachael Morton Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney

Back to top

Treatment for macroscopic nodal metastasis

WHAT IS THE APPROPRIATE TREATMENT FOR MACROSCOPIC (I.E. DETECTABLE CLINICALLY OR BY ULTRASOUND) NODAL METASTASIS?
Question lead: Professor Michael Henderson
Subcommittee members
Name Position/speciality
A/Professor T Michael Hughes Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital, NSW
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
A/Professor Andrew Spillane Associate Professor, Surgical Oncology, The University of Sydney
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC

Back to top

Treatment for satellite and in-transit metastatic melanoma

WHAT ARE THE MOST EFFECTIVE TREATMENTS FOR SATELLITE AND IN TRANSIT METASTATIC MELANOMA?
Question lead: Professor Michael Henderson
Subcommittee members
Name Position/speciality
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Professor Omgo Nieweg Surgeon, Melanoma Institute Australia, NSW
Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC

Back to top

Systemic therapy, immunotherapy and targeted therapies

WHAT IS THE ROLE OF ADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RESECTED STAGE 3 MELANOMA?
Question lead: Dr Matteo Carlino
Subcommittee members
Name Position/speciality
Dr Victoria Atkinson Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD
Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW
Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre, VIC
DOES SYSTEMIC DRUG THERAPY IMPROVE PROGRESSION FREE AND/OR OVERALL SURVIVAL IN UNRESECTABLE STAGE II AND STAGE IV MELANOMA?
Question lead: Professor Georgina Long
Subcommittee members
Name Position/speciality
Dr Matteo Carlino Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW
Professor Richard Kefford AM Professor of Cancer Medicine, Macquarie University, NSW
Professor Grant McArthur Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr Mark Shackleton Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW

Back to top

Radiotherapy

FOR PATIENTS WITH DISTANT METASTASIS (OTHER THAN BRAIN METASTASES), WHEN IS RADIOTHERAPY INDICATED?
Question lead: A/Professor Angela Hong
Subcommittee members
Name Position/speciality
Dr Gerald Fogarty Director, Radiation Oncology, Mater Hospital, NSW
Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital, NSW
IS ADJUVANT RADIOTHERAPY OF VALUE FOLLOWING RESECTION OF INVOLVED LYMPH NODES?
Question lead: Professor Graham Stevens
Subcommittee members
Name Position/speciality
Professor Bryan Burmeister Director, Radiation Oncology, Princess Alexandra Hospital, QLD
Dr Gerald Fogarty Director, Radiation Oncology, Mater Hospital, NSW
Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC

Back to top

Surgery

FOR PATIENTS WITH DISTANT METASTASES, WHEN IS SURGICAL THERAPY INDICATED?
Question lead: A/Prof Andrew Spillane
Subcommittee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney, NSW

Back to top

Brain metastases

WHAT IS THE RECOMMENDED SURGICAL APPROACH TO BRAIN METASTASES FOR PATIENTS WITH ADVANCED MELANOMA?
Question lead: Dr Brindha Shivalingam
Subcommittee members
Name Position/speciality
Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW
A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW
WHEN IS RADIOTHERAPY INDICATED FOR PATIENTS WITH DISTANT BRAIN METASTASES?
Question lead: A/Prof Angela Hong
Subcommittee members
Name Position/speciality
Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW
Dr Brindha Shivalingam Director of Neurosurgery, The Chris O’Brien Lifehouse; Consultant Neurosurgeon, Royal Prince Alfred Hospital and The Mater Hospital North Sydney
WHAT IS THE ROLE OF SYSTEMIC DRUG THERAPY IN THE MANAGEMENT OF ADVANCED MELANOMA PATIENTS WITH BRAIN METASTASES?
Question lead: Professor Georgina Long
Subcommittee members
Name Position/speciality
A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW
Dr Brindha Shivalingam Director of Neurosurgery, The Chris O’Brien Lifehouse; Consultant Neurosurgeon, Royal Prince Alfred Hospital and The Mater Hospital North Sydney
Dr Matteo Carlino Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW
Professor Richard Kefford AM Professor of Cancer Medicine, Macquarie University, NSW
Professor Grant McArthur Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr Mark Shackleton Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW

Back to top

Multidisciplinary care

IS MULTIDISCIPLINARY CARE OF VALUE IN THE MANAGEMENT OF MELANOMA?
Question lead: Prof John Thompson & Dr Gabrielle Williams

Back to top

Melanoma in pregnancy

HOW SHOULD MELANOMA IN PREGNANCY BE MANAGED?
Question lead: Dr Julie Howle
Subcommittee members
Name Position/speciality
A/Professor Kiarash Khosrotehrani Clinical Scientist, Centre for Clinical Research, The University of Queensland, QLD
Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW

Back to top


HOW SHOULD MELANOMA IN CHILDHOOD BE MANAGED?
Question lead: Dr Chris McCormack
Subcommittee members
Name Position/speciality
Dr Alex Varey Staff Specialist, Department of Plastic and Maxillofacial Surgery, Westmead Hospital, Sydney, Australia
Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW


HOW SHOULD MELANOCYTIC TUMOUR OF UNKNOWN MALIGNANT POTENTIAL (MELTUMP) BE MANAGED?
Question lead: Dr Alex Varey
Subcommittee members
Name Position/speciality
Professor Richard Scolyer Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
OCULAR MELANOMA
Question lead: A/Prof Max Conway
Subcommittee members
Name Position/speciality
Dr Michael Giblin Clinical Senior Lecturer, Clinical Opthalmology & Eye Health, Central Clinical School
Dr Svetlana Cherepanoff Consultant Pathologist & Leader, Ophthalmic Pathology Research Group, Brain and Mind Centre, The University of Sydney
MUCOSAL MELANOMA
Question lead: Professor Michael Henderson

Back to top

Acknowledgement

Sincere thanks to Professor Ian Olver AM who initiated the Melanoma Guidelines Revision Project in collaboration with Melanoma Institute Australia in 2014 in his role as Chief Executive Officer, Cancer Council Australia. Since February 2015, he has been Director, Sansom Institute for Health Research.

Back to top